阿立哌唑治疗精神分裂症的临床评价

目的: 评价国产阿立哌唑对精神分裂症的疗效与安全性。方法: 80例精神分裂症患者随机分为2组:阿立哌唑组40例,给予阿立哌唑10~ 20mg·d^-1,po,qd;氯氮平组40例,给予氯氮平300 ~500 mg·d^-1,po, Bid。采用阳性症状与阴性症状量表(PANSS)评价临床疗效、不良反应症状量表(TESS)评价不良反应,观察8周。结果: 阿立哌唑治疗后PANSS总分减分率为50.4%,有效率为87.5%;氯氮平PANSS总分减分率为49.4%,有效率为85.0%.两组总体疗效相当(P>0.05)。阿立哌唑对阴性症状起效较早。阿立哌唑组常见不良反应有锥体外系反应(EPS)(17.5%)、头痛(12.5%)、恶心呕吐(10%),但与氟氮平组比较差异无显著性(P>0.05),且程度较轻,无血象及糖代谢异常;与氯氮平组较多的过度镇静(37.5%)、流延(45%)、便秘(25%)、体重增加(25%)比较差异有显著性(P<0.05或P<0.01)。结论: 阿立哌唑是一种治疗精神分裂症安全有效的药物。

Clinical study of therapeutic effects of aripiprazole in treatment of patients with schizophrenia

AIM To evaluate the therapeutic effects and the safety of aripiprazole in the treatment of patients with schizophrenia.METHODS: 80 schizophrenic patients were randomly divided into two groups. Aripiprazole group was treated with 10-20 mg d " aripiprazole, poqd. Clozapine group was treated with clozapine 300~500 mg·d^-1, po, bid. Clinical effects were assessed with th Positive and Negative Syndrome Scale for8 weeks. Clinical effects were assessed with the Positive and Negative Syndrome Scale (PANSS), and side effects were assessed with the Treatment Emergent Symptom Scale (TESS) in following 8 weeks.RESULTS: Reduction rate in PANSS total scores in ariprazole group was 50.4%, and the efficacy was 87.5%. Reduction rate in PANSS total scoresin clozapine group was 49.4%, and the efficacy was 85%. The therapeutic effects were similar in the two groups (P > 0.05). There were some side effects such as EPS (17. 5%), headache (12. 5%), nausea and vomit-ing (10%) in aripiprazole group, but they were milderand the blood and glycometabolism was normal. Therewas no significant difference in two groups. Comparedwith the too much sedation (37.5%), secretion of paroid gland (45%), constipation (25%), gain weight(25%) in clozapine group, there was a significant differ-ence in two groups (P < 0.05 or P < 0.01).CONCLUSION: Aripiprazole is a safety and efficacy drug intreatment of patients with schizophrenia.